Healixa Appoints Diane Koontz to its Advisory Board
January 13, 2022
OptimizeRx Survey Addresses Treatment Selection, Discontinuation and Switching in Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer – an Indication with Limited Patient Population
December 15, 2021
Related Post
-
-
Healixa, Inc. (OTC: EMOR) Appoints Accomplished Independent Director to its Board in Step Towards National Securities Exchange Listing Requirements
January 11, 2022
-
OptimizeRx’s Evidence-Based Physician Engagement Solution Named One of the Most Innovative Products of the Year by PM360
December 29, 2021
-
OptimizeRx CEO Issues Open Letter to Shareholders Detailing the Completion of Internal Management Changes
December 22, 2021